Polaris Pharma

CA - San DiegoCDMO (Contract Manufacturing)1 H-1B visas (FY2023)

Focus: Polaris Pharma is a CDMO (Contract Development and Manufacturing Organization) headquartered in San Diego specializing in biologics manufacturing for oncology therapeutics. The company operates in the competitive CDMO segment supporting cancer drug development and production.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Polaris Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Polaris Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Less rigid rod

Kyphosis

N/A

Clinical Trials (1)

NCT01441999Proximal Junctional Kyphosis Following Long Instrumented Spinal Fusion: The Effect of Implant Selection

N/A

Help build intelligence for Polaris Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Oncology focus provides exposure to high-value, fast-growing therapeutic area with strong clinical and commercial momentum
CDMO model offers diverse project exposure across multiple client programs rather than single-pipeline dependency
San Diego location provides access to biotech talent hub and established life sciences infrastructure

Watch Out For

Zero active job openings at time of data snapshot suggests limited near-term hiring or potential contraction
Limited public visibility on funding, financials, and pipeline makes career trajectory and stability assessment difficult

Generated by Claude from Polaris Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

personalized, motivational messages

Cancer

N/A

Clinical Trials (1)

NCT01442285The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)

N/A

ADI-PEG 20

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT02875093Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Phase 1

ADI-PEG 20

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT02101593Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Phase 1

ADI-PEG 20

Solid Tumors

Phase 1

Clinical Trials (1)

NCT01497925Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

Phase 1

ADI PEG20

Soft Tissue Sarcoma

Phase 1

Clinical Trials (1)

NCT05813327Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Phase 1

ADI-PEG 20

Pleural Mesothelioma Malignant Advanced

Phase 1

Clinical Trials (1)

NCT02029690Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Phase 1

ADI-PEG 20

Acute Myeloid Leukemia, Adult

Phase 1

Clinical Trials (1)

NCT05001828Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Phase 1

ADI-PEG 20

HER2 Negative Metastatic Breast Cancer

Phase 1

Clinical Trials (1)

NCT01948843Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

Phase 1

ADI-PEG 20

Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT01665183Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Phase 1

Atezolizumab

Carcinoma, Non-Small-Cell Lung

Phase 1

ADI PEG20

Advanced Solid Cancers

Phase 1

Clinical Trials (1)

NCT03254732Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Phase 1

ADI-PEG 20

Advanced Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT02101580Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Phase 1

ADI-PEG 20

Argininosuccinate Synthetase Deficient

Phase 1

Clinical Trials (1)

NCT01528384Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient

Phase 1

ADI-PEG 20 plus modified FOLFOX6

Advanced Gastrointestinal (GI) Malignancies

Phase 1/2

Clinical Trials (1)

NCT02102022Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Phase 1/2

ADI-PEG 20

Non Small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT05616624ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2

RBIRT

Alcohol Abuse, Alcohol Dependence

Phase 2

Clinical Trials (1)

NCT02622984Remote Brief Intervention and Referrals to Treatment Service for Alcohol

Phase 2

ADI-PEG20

Nonalcoholic Steatohepatitis (NASH)

Phase 2

Clinical Trials (1)

NCT05842512Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Phase 2

STaRS

Substance Abuse

Phase 2

Clinical Trials (1)

NCT01488630Substance Treatment and HIV Testing and Referral System

Phase 2

ADI-PEG 20

Glioblastoma Multiforme (GBM)

Phase 2

Clinical Trials (1)

NCT04587830ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

Phase 2

ADI-PEG20

Obesity

Phase 2

Clinical Trials (1)

NCT05829239ADI-PEG20, Obesity and Prediabetes

Phase 2

ADI-PEG 20

Unresectable Hepatocellular Carcinoma

Phase 2

Clinical Trials (1)

NCT02006030Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Phase 2

ADI-PEG 20

Acute Myeloid Leukemia

Phase 2

Clinical Trials (1)

NCT01910012PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Phase 2

ADI-PEG 20

Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT01266018Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer